Survivor treatment selection bias in observational studies: Examples from the AIDS literature

Annals of Internal Medicine

Volumn 124, Issue 11, 1996, Pages 999-1005

  Glesby, Marshall J ^b   Hoover, Donald R ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OBSERVATION; PRIORITY JOURNAL; SURVIVAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; FEMALE; HEALTH STATUS; HUMANS; LIFE TABLES; MALE; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; SELECTION BIAS;

EID: 0030317304     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-124-11-199606010-00008     Document Type: Article

References (46)

1. Bacchetti P, Moss AR. Incubation period of AIDS in San Francisco. Nature. 1989;338:251-3.
2. Muñoz A, Wang MC, Bass S, Taylor JM, Kingsley LA, Chmiel JS, et al. Acquired immunodeficiency syndrome (AIDS)-free time after human immunodeficiency virus type 1 (HIV-1) seroconversion in homosexual men. Multicenter AIDS Cohort Study Group. Am J Epidemiol. 1989;130:530-9.
3. Schlesselman JJ, Stolley PD. Case-Control Studies: Design, Conduct, Analysis. New York: Oxford Univ Pr; 1982;124.
4. Graham NM, Zeger SL, Kuo V, Jacobson LP, Vermund SH, Phair JP, et al. Zidovudine use in AIDS-free HIV-1-seropositive homosexual men in the Multicenter AIDS Cohort Study (MACS), 1987-1989. J Acquir Immune Defic Syndr. 1991;4:267-76.
5. Lemp GF, Payne SF, Neal D, Temelso T, Rutherford GW. Survival trends for patients with AIDS. JAMA. 1990;263:402-6.
6. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med. 1991;324:1412-6.
7. d'Arminio Monforte A. Mainini F, Bini T, Cinque P, Formenti T, Lazzarin A, et al. Survival differences for 547 AIDS cases in Milan [Letter]. J Acquir Immune Defic Syndr. 1992;5:1276-7.
8. Magallon Martinez M, Ortega F, Pinilla J. AIDS and hemophilia: experience in the La Paz Hemophilia Center. Haemostasis. 1992;22:281-92.
9. Selwyn PA, Alcabes P, Hartel D, Buono D, Schoenbaum EE, Klein RS, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med. 1992;327: 1697-703.
10. Lemp GF, Hirozawa AM, Cohen JB, Derish PA, McKinney KC, Hernandez SR. Survival for women and men with AIDS. J Infect Dis. 1992;166:74-9.
11. Graham NM. Zeger SL, Park LP, Vermund SH, Detels R, Rinaldo CR, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med. 1992;326:1037-42.
12. Ragni MV, Kingsley LA, Zhou SJ. The effect of antiviral therapy on the natural history of human immunodeficiency virus infection in a cohort of hemophiliacs. J Acquir Immune Defic Syndr, 1992;5:120-6.
13. Buira E, Gatell JM, Miro JM, Batalla J, Zamora L, Mallolas J, et al. Influence of treatment with zidovudine (ZDV) on the long-term survival of AIDS patients. J Acquir Immune Defic Syndr. 1992;5:737-42.
14. Vella S, Gluliano M, Pezzotti P, Agresti MG, Tomino C, Floridia M, et al. Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. Italian Zidovudine Evaluation Group. JAMA. 1992;267:1232-6.
15. Portegies P, Enting RH, de Gans J, Algra PR, Derix MM, Lange JM, et al. Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS. 1993;7:669-75.
16. Survival of patients receiving Zidovudine before or after AIDS diagnosis: results of a German multicenter study. German AIDS Study Group. Clin Invest. 1994;72:111-6.
17. Santos B, Beck EJ, Peixoto MF. Survival and medical intervention in southern Brazilian AIDS patients. Int J STD AIDS. 1994;5:279-83.
18. Colford JM Jr, Ngo L, Tager I. Factors associated with survival in human immunodeficiency virus-infected patients with very low CD4 counts. Am J Epidemiol. 1994;139:206-18.
19. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA. 1994;271:1083-7.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53:457-81.
21. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst. 1980;64:1263-72.
22. Brookmeyer R, Gail MH, Polk BF. The prevalent cohort study and the acquired immunodeficiency syndrome. Am J Epidemiol. 1987;126:14-24.
23. Fätkenheuer G, Stützer H, Salzberger B, Schrappe M. Zidovudine and the natural history of AIDS [Letter]. N Engl J Med. 1991;325:1311-3.
24. Pike MC, Buckley JD, Mosley JW. Zidovudine and the natural history of AIDS [Letter]. N Engl J Med. 1991;325:1311-3
25. Hirschel B. Early Zidovudine and survival in HIV infection [Letter]. N Engl J Med. 1992;327:814
26. Gail MH, Mark SD. Early Zidovudine and survival in HIV infection [Letter]. N Engl J Med. 1992;327:815.
27. Phillips AN, Keenlyside R, Johnson AM. The effect of antiviral therapy on the natural history of HIV infection [Letter]. J Acquir Immune Defic Syndr. 1992;5:1065-6,
28. Fischi MA, Rlchman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskln OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317:185-91.
29. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled study in persons with fewer than 500 CD4-positive cells per cubic milliliter. N Engl J Med. 1990;322:941-9.
30. Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, et al. A controlled trial of early versus late treatment with Zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med. 1992;326:437-43.
31. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet. 1994;871-81.
32. Moore RD, Chaisson RE, Hidalgo J. The efficacy of zidovudine is time limited [Letter]. JAMA. 1994;272:1001.
33. Graham NM, Zeger SL, Park LP. Early zidovudine and survival in HIV infection [Letter], N Engl J Med. 1992;327:815-6.
34. Lundgren JD, Phillips AN, Pedersen C, Clumeck N, Gatell JM, Johnson AM, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA. 1994;271:1088-92.
35. Saah AJ, Hoover DR, He Y, Kingsley LA, Phair JP. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr. 1994;7:287-95.
36. Robins JM, Blevins D, Ritter G, Wulfsohn M. G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology. 1992;3:319-36.
37. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society. 1972;34:187-220.
38. Kopec-Schrader E, Tindall B, Learmont J, Wylie B, Kaldor JM. Development of AIDS in people with transfusion-acquired HIV infection. AIDS. 1993; 7;1009-13.
39. Stein DS, Graham NM, Park LP, Hoover DR, Phair JP, Detels R, et al. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study. Ann Intern Med. 1994;121:100-8.
40. Gallant JE, Moore RD, Keruly J, Richman DD, Chaisson RE. Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group. J Infect Dis. 1996;172:346-52.
41. Tsai WY, Jewell NP, Wang MC. A note on the product-limit estimator under right censoring and left truncation. Biometrika. 1987;74:883-5.
42. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal WklyRep. 1993;41(RR-17):1-13.
43. Choi S, Lagakos SW, Schooley RT, Volberding PA. CD4 Lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med. 1993;118: 674-80.
44. De Gruttola V, Wulfsohn M, Fischl MA, Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDSrelated complex. J Acquir Immune Defic Syndr. 1993;6:359-65.
45. Kirby AJ, Muñoz A, Detels R, Armstrong JA, Saah A, Phair JP. Thrush and fever as measures of immunocompetence in HIV-1-infected men. J Acquir Immune Defic Syndr. 1994;7:1242-9.
46. Mark SD, Robins JM. Estimating the causal effect of smoking cessation in the presence of confounding factors using a rank preserving structural failure time model. Stat Med. 1993;12:1605-28.